- Home
- OPT vs ABVX Comparison
OPT vs ABVX Comparison
Compare OPT & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- ABVX
- Stock Information
- Founded
- OPT 1984
- ABVX 2013
- Country
- OPT Australia
- ABVX France
- Employees
- OPT N/A
- ABVX N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- ABVX
- Sector
- OPT Health Care
- ABVX
- Exchange
- OPT Nasdaq
- ABVX Nasdaq
- Market Cap
- OPT 767.9M
- ABVX 722.3M
- IPO Year
- OPT 2020
- ABVX N/A
- Fundamental
- Price
- OPT $3.22
- ABVX $7.80
- Analyst Decision
- OPT Strong Buy
- ABVX Strong Buy
- Analyst Count
- OPT 1
- ABVX 6
- Target Price
- OPT $12.00
- ABVX $38.67
- AVG Volume (30 Days)
- OPT 13.0K
- ABVX 119.0K
- Earning Date
- OPT 08-30-2024
- ABVX 09-09-2024
- Dividend Yield
- OPT N/A
- ABVX N/A
- EPS Growth
- OPT N/A
- ABVX N/A
- EPS
- OPT N/A
- ABVX N/A
- Revenue
- OPT $261,859.00
- ABVX $9,676,417.00
- Revenue This Year
- OPT N/A
- ABVX $31.67
- Revenue Next Year
- OPT $46,864.64
- ABVX $1,189.66
- P/E Ratio
- OPT N/A
- ABVX N/A
- Revenue Growth
- OPT N/A
- ABVX 100.87
- 52 Week Low
- OPT $1.79
- ABVX $7.11
- 52 Week High
- OPT $5.45
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- OPT 40.67
- ABVX 38.81
- Support Level
- OPT $3.15
- ABVX $7.11
- Resistance Level
- OPT $3.78
- ABVX $8.18
- Average True Range (ATR)
- OPT 0.18
- ABVX 0.48
- MACD
- OPT -0.00
- ABVX -0.01
- Stochastic Oscillator
- OPT 25.91
- ABVX 36.13
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.